Elanco Animal Health (NASDAQ:ELAN) updated its FY 2019 earnings guidance on Thursday. The company provided earnings per share guidance of $1.02-1.12 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.08. The company issued revenue guidance of $3.08-3.14 billion, compared to the consensus revenue estimate of $3.13 billion.
Several research firms have recently commented on ELAN. Zacks Investment Research lowered Elanco Animal Health from a buy rating to a hold rating in a report on Tuesday, March 5th. UBS Group began coverage on Elanco Animal Health in a report on Wednesday, March 20th. They set a sell rating and a $28.00 target price for the company. Bank of America raised Elanco Animal Health from a neutral rating to a buy rating and set a $30.95 target price for the company in a report on Monday, March 18th. William Blair began coverage on Elanco Animal Health in a report on Monday, February 11th. They set a market perform rating and a $29.71 target price for the company. Finally, Argus began coverage on Elanco Animal Health in a report on Tuesday, January 15th. They set a buy rating and a $37.00 target price for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. Elanco Animal Health currently has a consensus rating of Hold and a consensus price target of $33.22.
NASDAQ:ELAN opened at $31.39 on Thursday. Elanco Animal Health has a 52 week low of $28.00 and a 52 week high of $37.61.
Elanco Animal Health (NASDAQ:ELAN) last posted its earnings results on Wednesday, February 6th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.03. The company had revenue of $799.30 million for the quarter, compared to the consensus estimate of $804.07 million. During the same period last year, the company posted $0.12 earnings per share. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year.
In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was acquired at an average cost of $31.43 per share, with a total value of $628,600.00. The transaction was disclosed in a filing with the SEC, which is available through this link.
Elanco Animal Health Company Profile
There is no company description available for Elanco Animal Health Inc
Featured Article: Quiet Period
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.